
Company Website:
https://mindmed.co/
NEW YORK -- (Business Wire)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:
- Stifel 2025 Healthcare Conference
- Jefferies Global Healthcare Conference in London
- 8th Annual Evercore Healthcare Conference
- Piper Sandler 37th Annual Healthcare Conference
Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health.
MindMed trades on NASDAQ under the symbol MNMD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251105303331/en/
Contacts:
Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co
Media:
media@mindmed.co
Source: Mind Medicine (MindMed) Inc.
© 2025 Canjex Publishing Ltd. All rights reserved.